FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2183683973> ?p ?o ?g. }

• W2183683973 endingPage "1334" @default.
• W2183683973 startingPage "1323" @default.
• W2183683973 abstract "The aim of this randomised trial was to evaluate the activity and toxicity of a biweekly regimen including 6S-leucovorin-modulated 5-fluorouracil (LFA-5-FU), combined with either irinotecan (CPT-11 + LFA 5-FU) or raltitrexed (Tomudex) (TOM + LFA-5-FU), in advanced colorectal cancer patients, and to make a preliminary comparison of both these experimental regimens with a biweekly administration of LFA-5-FU modulated by methotrexate (MTX + LFA-5-FU).One hundred fifty-nine patients with advanced colorectal carcinoma previously untreated for the metastatic disease (34 of them previously exposed to adjuvant 5-FU) were randomly allocated to receive: CPT-11, 200 mg/m2 i.v. on day 1, followed on day 2 by LFA, 250 mg/m2 i.v. infusion and 5-FU, 850 mg/m2 s i.v. bolus (arm A); TOM, 3 mg/m2 i.v. on day 1, followed on day 2 by LFA, 250 mg/m2 i.v. infusion and 5-FU, 1050 mg/m2 i.v. bolus (arm B); or MTX, 750 mg/m2 i.v. on day 1, followed on day 2 by LFA, 250 mg/m2 i.v. infusion and 5-FU, 800 mg/m2 i.v. bolus (arm C). Courses were repeated every two weeks in all arms of the trial. Response rate (RR) was evaluated after every four courses. The sample size was defined to have an 80% power to detect a 35% RR for each experimental treatment, and to show a difference of at least 4% in RR with the standard treatment if the true difference is 15% or more.The RRs were: 34% (95% confidence interval (95%, CI): 21%-48%) in arm A, including 3 complete responses (CRs) and 15 partial responses (PRs), 24% (95% CI: 14%-38%) in arm B, including 2 CRs and 11 PRs, and 24% (95% CI: 14%-38%), with 2 CRs and 11 PRs, in arm C. After a median follow-up time of 62 (range 18-108) weeks, the median time to progression was 38, 25, and 27 weeks for arm A, B, and C, respectively. With 94 patients still alive, the one-year probability of survival was 61%, 54%, and 59%, respectively. WHO grade 3 or 4 neutropenia and diarrhoea affected 46% and 16%, respectively, of patients treated with CPT-11 + LFA 5-FU. Median relative dose intensity over eight cycles (DI8) was 78% for CPT-11 and 82% for 5-FU. Severe toxicities of TOM + LFA-5-FU were neutropenia (16%) and diarrhoea (16%), but median relative DI8 was 93% for TOM, and 82% for 5-FU.CPT-11 + LFA-5-FU compares favorably in term of activity and toxicity with other combination regimens including CPT-11 and continuous infusional 5-FU. The hypothesis of a RR 15% higher than the MTX + LFA-5-FU treatment can not be ruled out after this interim analysis. The TOM + LFA 5-FU regimen showed a RR and a toxicity profile very close to the MTX + LFA 5-FU combination, and dose not deserve further evaluation in advanced colorectal cancer patients." @default.
• W2183683973 created "2016-06-24" @default.
• W2183683973 creator A5009130863 @default.
• W2183683973 creator A5010499606 @default.
• W2183683973 creator A5021225962 @default.
• W2183683973 creator A5031898133 @default.
• W2183683973 creator A5033454821 @default.
• W2183683973 creator A5036019590 @default.
• W2183683973 creator A5036443897 @default.
• W2183683973 creator A5040974455 @default.
• W2183683973 creator A5047430414 @default.
• W2183683973 creator A5051722602 @default.
• W2183683973 creator A5056559714 @default.
• W2183683973 creator A5067058355 @default.
• W2183683973 creator A5073695437 @default.
• W2183683973 creator A5088304855 @default.
• W2183683973 creator A5090055323 @default.
• W2183683973 date "2000-10-01" @default.
• W2183683973 modified "2023-09-24" @default.
• W2183683973 title "Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase II–III randomized trial" @default.
• W2183683973 cites W1840238080 @default.
• W2183683973 cites W1918961940 @default.
• W2183683973 cites W1952371628 @default.
• W2183683973 cites W1970325604 @default.
• W2183683973 cites W1971325806 @default.
• W2183683973 cites W2006824814 @default.
• W2183683973 cites W2029409133 @default.
• W2183683973 cites W2030818307 @default.
• W2183683973 cites W2088971961 @default.
• W2183683973 cites W2096122707 @default.
• W2183683973 cites W2106482770 @default.
• W2183683973 cites W2110519215 @default.
• W2183683973 cites W2119270435 @default.
• W2183683973 cites W2128447158 @default.
• W2183683973 cites W2167739714 @default.
• W2183683973 cites W2167805334 @default.
• W2183683973 cites W2235063564 @default.
• W2183683973 cites W2330813625 @default.
• W2183683973 cites W2414944519 @default.
• W2183683973 cites W2602544133 @default.
• W2183683973 cites W3205607949 @default.
• W2183683973 cites W4238668552 @default.
• W2183683973 cites W4293241248 @default.
• W2183683973 doi "https://doi.org/10.1023/a:1008375705484" @default.
• W2183683973 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11106123" @default.
• W2183683973 hasPublicationYear "2000" @default.
• W2183683973 type Work @default.
• W2183683973 sameAs 2183683973 @default.
• W2183683973 citedByCount "24" @default.
• W2183683973 countsByYear W21836839732012 @default.
• W2183683973 countsByYear W21836839732013 @default.
• W2183683973 countsByYear W21836839732017 @default.
• W2183683973 crossrefType "journal-article" @default.
• W2183683973 hasAuthorship W2183683973A5009130863 @default.
• W2183683973 hasAuthorship W2183683973A5010499606 @default.
• W2183683973 hasAuthorship W2183683973A5021225962 @default.
• W2183683973 hasAuthorship W2183683973A5031898133 @default.
• W2183683973 hasAuthorship W2183683973A5033454821 @default.
• W2183683973 hasAuthorship W2183683973A5036019590 @default.
• W2183683973 hasAuthorship W2183683973A5036443897 @default.
• W2183683973 hasAuthorship W2183683973A5040974455 @default.
• W2183683973 hasAuthorship W2183683973A5047430414 @default.
• W2183683973 hasAuthorship W2183683973A5051722602 @default.
• W2183683973 hasAuthorship W2183683973A5056559714 @default.
• W2183683973 hasAuthorship W2183683973A5067058355 @default.
• W2183683973 hasAuthorship W2183683973A5073695437 @default.
• W2183683973 hasAuthorship W2183683973A5088304855 @default.
• W2183683973 hasAuthorship W2183683973A5090055323 @default.
• W2183683973 hasBestOaLocation W21836839731 @default.
• W2183683973 hasConcept C121608353 @default.
• W2183683973 hasConcept C123321153 @default.
• W2183683973 hasConcept C126322002 @default.
• W2183683973 hasConcept C141071460 @default.
• W2183683973 hasConcept C168563851 @default.
• W2183683973 hasConcept C204243189 @default.
• W2183683973 hasConcept C2776694085 @default.
• W2183683973 hasConcept C2776907518 @default.
• W2183683973 hasConcept C2778496288 @default.
• W2183683973 hasConcept C2779268555 @default.
• W2183683973 hasConcept C2780259306 @default.
• W2183683973 hasConcept C2780456651 @default.
• W2183683973 hasConcept C2781413609 @default.
• W2183683973 hasConcept C43376680 @default.
• W2183683973 hasConcept C526805850 @default.
• W2183683973 hasConcept C71924100 @default.
• W2183683973 hasConcept C90924648 @default.
• W2183683973 hasConceptScore W2183683973C121608353 @default.
• W2183683973 hasConceptScore W2183683973C123321153 @default.
• W2183683973 hasConceptScore W2183683973C126322002 @default.
• W2183683973 hasConceptScore W2183683973C141071460 @default.
• W2183683973 hasConceptScore W2183683973C168563851 @default.
• W2183683973 hasConceptScore W2183683973C204243189 @default.
• W2183683973 hasConceptScore W2183683973C2776694085 @default.
• W2183683973 hasConceptScore W2183683973C2776907518 @default.
• W2183683973 hasConceptScore W2183683973C2778496288 @default.
• W2183683973 hasConceptScore W2183683973C2779268555 @default.
• W2183683973 hasConceptScore W2183683973C2780259306 @default.
• W2183683973 hasConceptScore W2183683973C2780456651 @default.

• next